GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Market Cap	8.87B -11.3%
Revenue (ttm)	96.97M -56.6%
Net Income	-1.52B
EPS	-4.32
Shares Out	370.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,669,554
Open	23.30
Previous Close	22.52
Day's Range	22.82 - 24.40
52-Week Range	17.58 - 52.90
Beta	n/a
Analysts	Strong Buy
Price Target	51.03 (+112.98%)
Est. Earnings	Dec 17, 2026

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 159
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2595

Financial Performance

In 2025, HKG:2595's revenue was 130.27 million, an increase of 24.42% compared to the previous year's 104.70 million. Losses were -1.79 billion, 164.8% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 5 analysts, the average rating for 2595 stock is "Strong Buy." The 12-month stock price target is $51.03, which is an increase of 112.98% from the latest price.

Price Target

$51.03

(112.98% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error